Alexion has acquired the developer of the antidote of rivaroxaban

The company Alexion announced the agreement for the acquisition of Portola Pharmaceuticals and the rights to its only approved drug, the antidote to the anticoagulant to rivaroxaban. The value of the transaction is $ 1.4 billion, says FiercePharma.

Under the agreement, Portola Pharmaceuticals shareholders will receive $ 18 for each security, which is 131% more that the market value of a share of farmerette.

In the center of the transaction was andersonet alpha (andexanet alfa) is a antidote to the commonly used anticoagulants to rivaroxaban and apixaban. Although the market will undecane while the alpha uses small demand, Alexion sees its potential.

The drug was approved by the FDA in 2018, until then did not exist a specific antidote inhibitors of coagulation factor Ha, which is necessary to assist patients in emergency situations, for example to prevent bleeding or in preparation for surgery. In clinical studies, it was shown that intravenous administration of alpha andersonet will immediately neutralize the anticoagulant effect of inhibitors of clotting factor Ha in healthy volunteers aged 50-75 years.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]